Supreme Court wrestles with who can sue over FDA’s mifepristone rules and the proper scope of relief

The U.S. Supreme Court heard argument in a high‑stakes challenge to the Food and Drug Administration’s 2016 and 2021 changes to the conditions for using mifepristone, focusing heavily on whether the plaintiffs have Article III standing and on the scope of any judicial remedy. The government told the court that respondents lack standing because their theory depends on an attenuated chain of contingencies and “only an exceptionally small number” of patients suffer complications that could plausibly reach the doctors who say they would be harmed.

Why it matters: The threshold question of standing determines whether a court may evaluate the legality of agency decisions. If the court accepts the government’s argument that the asserted injuries are speculative and not traceable to FDA’s incremental changes, it could block review of similar challenges and limit courts’ ability to second‑guess agency safety judgments. If the court finds standing, it must still decide whether a nationwide vacatur or a narrower remedy is appropriate.

Government’s argument: During the opening, the Solicitor General (transcript: General Prelogar) said FDA relied on “dozens of studies involving tens of thousands of women” and that respondents “do not identify any evidence that the agency overlooked.” On standing, the SG argued respondents abandoned the statistical‑theory approach used below and now must point to a specific doctor facing imminent harm; the government called the respondents’ theory too “attenuated” and said federal conscience protections and existing tort and agency processes provide alternative protections.

Respondents’ position: Counsel for the doctors and advocacy groups argued that named OB/GYN hospitalists (they identified Dr. Francis and Dr. Scott in the record) and their organizations have suffered and will suffer diversion of resources, emotional harms, and repeated emergency‑room encounters tied to the removal of certain in‑person requirements. Respondents pointed to FDA statements and studies they say show increases in emergency‑room visits and surgical interventions after changes to the REMS (Risk Evaluation and Mitigation Strategy).

Justices’ concerns and testing: Several justices pressed both sides for concrete examples. Justice Jackson suggested the asserted conscience injury and the nationwide remedy are mismatched—if doctors’ injury is a conscience violation, she said, the natural remedy would be an exemption rather than a rule that prevents everyone nationwide from obtaining the drug. Other justices (including Thomas, Alito, Kagan, Barrett, and Sotomayor) probed whether organizational diversion of resources can create redressable injury and how to measure when a probabilistic risk becomes “certainly impending.”

Remedy questions: The court repeatedly returned to what relief would be proper: whether a court could tailor relief to the parties before it or whether the only effective relief for non‑regulated plaintiffs would be an agency‑wide vacatur. Respondents urged that vacatur was appropriate under equitable principles when non‑regulated parties lack other avenues to obtain relief; the government warned that nationwide relief would displace agency judgment and impose broad harms.

Next steps: The hearing ended with rebuttal from the Solicitor General reiterating the absence of specific, past conscience violations in the record and the risk of displacing regulatory schemes with national injunctions. The case is submitted.